Sources

13 Total Sources

FDA Approves Rasonque for Metastatic Pancreatic Cancer, Nearly Doubling Survival to 13 Months

Left100%

abcnews.com1h ago

FDA Approves Daraxonrasib (Rasonque) for Advanced Metastatic Pancreatic Cancer

The Washington Post2h ago

FDA Approves Daraxonrasib for Pancreatic Cancer, Doubling Survival

The New York Times3h ago

F.D.A. Approves Daraxonrasib for Advanced Pancreatic Cancer, Extending Patient Lives

Two New Drugs Offer Hope for Pancreatic Cancer

FDA approves Rasonque, pancreatic cancer drug expected to extend lives

app.dealroom.co2h ago

Revolution Medicines wins FDA approval for Rasonque, the first drug to target the genetic driver of pancreatic cancer | Dealroom.co

The Associated Press1h ago

FDA Approves Daraxonrasib for Advanced Pancreatic Cancer, Doubling Survival

Cancer Network3h ago

FDA Approves Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer | CancerNetwork

Targeted Oncology3h ago

FDA Allows Expanded Access to Daraxonrasib for PDAC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

dongascience.com3h ago

Revolution Medicines drug daraxonrasib doubles pancreatic cancer survival time - DongA Science

Predicting How Today's FDA Approval of Zanidatamab Will Affect Gastric Cancer Care

Pancreatic cancer is one of the deadliest and most difficult cancers to treat. The University of Chicago Medicine is now offering a new oral medication that can help extend patients' lives. Oncologist

FDA Approves Revolution Medicines' Rasonque for Metastatic Pancreatic Cancer